

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Sire Bioscience Inc. (the "Issuer")

Trading Symbol: SIRE

Number of Outstanding Listed Securities: 400,222,327

Date: November 6, 2019

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

- 1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

See Item 2 below for a complete overview and discussion of the Issuer's activities for the month of October 2019.

- 2. Provide a general overview and discussion of the activities of management.

On October 30, 2019, the Issuer announced the appointment of Domenic Crudo as CFO and Corporate Secretary following the resignation of Sean McGrath effective October 31, 2019.

The Board wishes to thank Mr. McGrath for his many contributions to the Issuer over the past year and a half, particular in connection with the execution and completion of the reverse takeover of Best Cannabis Products Inc. and the formation of the Issuer.

Mr. Crudo is a successful, strategic, financial and accounting executive with over 30 years' experience as the CFO for both public and private companies. The companies he has worked with have ranged in size from startups to multinationals. Mr. Crudo's industry experience includes manufacturing and processing, consumer packaged goods, telephony and technology, retail/loss prevention, as well as other companies in technology, retail and marketing. Mr. Crudo is a successful entrepreneur having co-founded and taken his own startup company public. Most recently he worked closely with other successful start-ups in consumer-packaged goods (Flow Water), technology companies (Soof Inc.) as well as food, beverage and enhanced nutritional product companies. Mr. Crudo has strong practical knowledge about IFRS, ASPE, US Gaap, regulatory reporting, taxation across various geographies, financial modeling and corporate capital structures. Mr. Crudo's extensive experience with boards, investors and other stakeholders has resulted in successfully obtaining equity and debt financing for a variety of companies via a variety of financial transactions. Mr. Crudo's experience also includes leading international growth via organic means and mergers and acquisitions. Additional responsibilities that Mr. Crudo successfully performs includes contract negotiations, management of risk/legal/audit services, management of IT, Human resources, facilities management and property development.

Mr. Crudo obtained his Bachelor of Commerce from the University of Toronto and is a Chartered Professional Accountant (Chartered Accountant).

About Sire Bioscience:

Sire's principal business activity is to engage in the investment, production of and sale of hemp for CBD extraction. Sire has its wholly-owned, state-of-the-art facility in Leamington, Ontario – a preeminent locale for hemp cultivation in Canada. The land parcel includes 50 acres of prime horticultural land, with a 160,000 sq. ft facility of combined greenhouse and indoor space. Our goal is to become a vertically integrated CPG life science company with our "House of Brands" offering. Sire is headquartered in Toronto, Ontario and is backed by a group of successful entrepreneurs who have extensive experience in the areas of manufacturing, logistics, and renewable energy.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

None.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None.

8. Describe the acquisition of new customers or loss of customers.

None.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None.

14. Provide details of any securities issued and options or warrants granted.

N/A.

15. Provide details of any loans to or by Related Persons.

None.

16. Provide details of any changes in directors, officers or committee members.

As mentioned in Item 2 above, effective October 31, 2019, Domenic Crudo was appointed as CFO and Corporate Secretary and Sean McGrath resigned as CFO of the Issuer.

17. Discuss any trends, which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

N/A.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: **November 6, 2019**_____.

Domenic Crudo
Name of Director or Senior Officer

"Domenic Crudo"
Signature

CFO & Corporate Secretary
Official Capacity

<i>Issuer Details</i> Name of Issuer	For Month End	Date of Report YY/MM/DD
Sire Bioscience Inc.	October 2019	19/11/06
Issuer Address 213 Sterling Road, Suite 206		
City/Province/Postal Code Toronto, ON M6R 2B2	Issuer Fax No. N/A	Issuer Telephone No. (416) 262.0871
Contact Name Domenic Crudo	Contact Position CFO & Corporate Secretary	Contact Telephone No. (416) 262.0871
Contact Email Address ir@sirebioscience.com	Web Site Address www.sirebioscience.com	